Table.
Demographics, immunosuppressive treatments, and outcomes of children with kidney disease and COVID-19
| Participants with COVID-19 (n=18) | ||
|---|---|---|
| Demographics | ||
| Median age, years | 11·5 (6·0–14·0) | |
| Sex | ||
| Boys | 11 (61%) | |
| Girls | 7 (39%) | |
| Underlying kidney disease and reason for immunosuppression | ||
| Kidney transplantation | 11 (61%) | |
| Nephrotic syndrome | 3 (17%) | |
| Antineutrophil cytoplasmic antibody-associated vasculitis | 2 (11%) | |
| Atypical haemolytic uraemic syndrome | 1 (6%) | |
| End-stage kidney disease with inflammatory bowel disease | 1 (6%) | |
| Immunosuppressive treatments | ||
| Glucocorticoids | 12 (67%) | |
| Tacrolimus | 12 (67%) | |
| Mycophenolate Mofetil | 9 (50%) | |
| Rituximab | 3 (17%) | |
| Azathioprine | 2 (11%) | |
| Basiliximab | 1 (6%) | |
| Cyclophosphamide | 1 (6%) | |
| Ciclosporin | 1 (6%) | |
| Everolimus | 1 (6%) | |
| Adalimumab | 1 (6%) | |
| Eculizumab | 1 (6%) | |
| COVID-19 | ||
| Symptoms | ||
| Fever | 13 (72%) | |
| Cough | 11 (61%) | |
| Rhinitis | 5 (28%) | |
| Diarrhoea | 3 (17%) | |
| Shortness of breath | 0 (0%) | |
| Median time since the onset of illness at the time of reporting, days | 5·0 (2·0–9·5) | |
| Maximal respiratory support required | ||
| High-flow nasal cannula oxygen | 1 (6%) | |
| Supplemental face mask oxygen | 2 (11%) | |
| None | 15 (83%) | |
| Outcome | ||
| Admitted to intensive care | 0 (0%) | |
| Admitted to hospital | 11 (61%) | |
| Not admitted to hospital at any point | 7 (39%) | |
Data are n (%) or median (IQR). COVID-19=coronavirus disease 2019.